Clinical trial
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00031616 · NewBiotics, Industry · Unknown status
Key facts
| NCT number | NCT00031616 |
|---|---|
| Title | NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
| Official title | A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers |
| Lead sponsor | NewBiotics, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | brivudine phosphoramidate |
| Start date | Dec 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: